Answers are grounded in this paper and cite their sources.
In this trial, pirtobrutinib showed efficacy in patients with heavily pretreated CLL or SLL who had received a covalent BTK inhibitor. The most common adverse events were infections, bleeding, and neutropenia. (Funded by Loxo Oncology; BRUIN ClinicalTrials.gov number, NCT03740529.).
No takes yet. Share an insight, caveat, or question.
Mato et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: